Adjunct VR Pain Management in Acute Brain Injury

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-05

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Severe and refractory pain after acute injury is a known-risk factor for chronic opioid use disorder. In this study, the investigators will use Virtual Reality (VR) immersion as a non-pharmacological adjunct to treat pain associated with acute traumatic injuries, including traumatic brain injury. The investigators hypothesize that VR therapy will decrease pain and reduce opioid use in patients with acute traumatic injuries, including TBI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Virtual Reality Analgesia In Trauma Rehab

NCT03894592

Virtual Reality Musculoskeletal Pain Opioid Use +3 more

UNKNOWN NA

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

NCT04851301

Pain Virtual Reality Placebo +1 more

RECRUITING PHASE1/PHASE2

Virtual Reality Therapy for Pain Management at the Emergency Department

NCT06089642

Pain, Acute

UNKNOWN NA

Virtual Reality for Appendectomy Pain

NCT04357132

Appendix Rupture Pain Pain, Postoperative

COMPLETED NA

Pain Control After Trauma

NCT00739076

Trauma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each participant will undergo one VR session and two control sessions. The VR session will take place in a commercially available VR environment, the Blu, and last 20-30 minutes (VR Blu). The control sessions will include a 2D-tablet based session that mimics the VR content (Tablet Blu) and a content-less placement of the VR headset (VR Blank). The order of these sessions will be randomized across participants are intended to complete all sessions.

Each participant will complete a pre-study questionnaire to elicit their prior experience with the virtual reality as well as measures of gaming addiction/engagement, boredom, and expectancy. These scales will help us determine which patient-level factors predict response to VR. Before and after each session, participants will complete validated scales of pain, nausea, and anxiety.. Pre- and Post-VR opioid use will be recorded. Basic vital signs including heart rate, blood pressure, and respiratory rate, will be recorded before and after each session to monitor autonomic response. Advanced measures of autonomic response will include heart rate variability,,and pupillometry metrics. At the conclusion of all sessions, participants will complete another questionnaire to document their subjective experience of using VR (perceived effectiveness)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Injury Headaches Posttraumatic Trauma Pain, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Within-Subjects Design. All participants (single group, 1 arm) intended to complete all three sessions (interventions) in randomized order. At least 4 hours were required to pass between each session to allow for washout.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions will take place in patient rooms with curtain pulled and sign to mask active intervention vs. control intervention from care providers.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All patients

All patients were intended to engage in three different 20-30 min sessions run by research coordinators and spaced a minimum of 4 hours apart to allow for washout of effects, including 1) a commercially available, immersive VR environment, theBlu (WEVR, Inc, Venice, California, USA) delivered via Oculus Rift (Oculus VR, Irvine, California, USA) headset (VR Blu), 2) a non-immersive two-dimensional mimic delivered via a tablet computer (Tablet Blu), and 3) a VR control session delivered via a content-less Oculus Rift headset (VR Blank). The three sessions were run by research coordinators and spaced a minimum of 4 hours apart. The intervention order was counterbalanced using a randomized sequence generator.

Group Type EXPERIMENTAL

Virtual Reality Session (VR Blu)

Intervention Type BEHAVIORAL

20-30 minute session of virtual reality immersive content.

Tablet-based Session (Tablet Blu)

Intervention Type BEHAVIORAL

20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.

Use of Virtual Reality Head Mounted Display without Content (VR Blank)

Intervention Type BEHAVIORAL

20-30 minutes session using head mounted display to reduce light and sound.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Virtual Reality Session (VR Blu)

20-30 minute session of virtual reality immersive content.

Intervention Type BEHAVIORAL

Tablet-based Session (Tablet Blu)

20-30 minute session of tablet-based content that mimics the content from virtual reality sessions.

Intervention Type BEHAVIORAL

Use of Virtual Reality Head Mounted Display without Content (VR Blank)

20-30 minutes session using head mounted display to reduce light and sound.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Traumatic Injury (including but not limited to traumatic brain injury)
* Age greater than or equal to 18 years-old
* Endorsing at least moderate pain as defined by documentation of at least one numeric rating pain scale score of 3 or more in the last 24 hours.
* Glasgow Coma Scale of 15
* Expected to stay in the hospital for at least 12 hours after enrollment